At its investor conference on the 15th, EirGenix announced positive momentum for 2024. Senior Vice President Chang Chih-Jung noted that the number of contracts signed so far this year has already surpassed that of 2023. As these contracts begin to be executed in the third and fourth quarters, along with contributions from the CDMO business, the company expects significant support for its operations in the second half of the year.

Chang pointed out that many of the company’s recent clients are well-known pharmaceutical firms, with orders focused on late-stage or near-commercial products. Additionally, as patents for several biologics approach expiration, healthcare systems in Europe and the U.S. are facing potential surges in spending. Regulatory policies are adapting accordingly, which may create opportunities for EirGenix to benefit.

He further highlighted EirGenix’s strengths in recent years in initiating biosimilar development projects and its extensive experience in regulatory registration. With contract execution progressing and CDMO production capacity steadily ramping up, the company anticipates continued growth in the latter half of the year.

Chairman Lee-Cheng Liu stated that beginning in the third quarter, production at the Xizhi facility will intensify, while two mammalian cell production lines at the Zhubei facility will come online. The first line will focus on manufacturing the company’s own products, EG12014 and completing PPQ for EG1206A, preparing for future commercial production. The second line has already started producing biosimilars for CDMO clients, with plans to file for commercial production soon.

Addressing recent currency fluctuations, Liu noted that EirGenix's foreign exchange exposure remains within controllable limits and has not significantly impacted profitability. The company will continue to monitor global economic and political developments and central bank policies, adjusting its hedging strategies as needed.

Regarding tariffs, Liu explained that since EirGenix primarily provides CDMO services to U.S. clients, including materials for clinical use, the impact from tariffs has been minimal.

Resource: 台康生合約落實貢獻、CDMO挹注 助攻下半年營運